Hurum휴럼

Hurum's shares have fallen sharply over the past year and the company is loss-making on a trailing basis, though the filings show a share buyback and an extraordinary shareholders' meeting.

Hurum makes health functional foods and related products, including the TRULAC probiotic and VEGERGY supplement, sold through home shopping, online, retail and military channels. Trailing results to H1 2026 show revenue of about ₩94.9B but a small operating profit of about ₩15M and a net loss of about ₩532M, with borrowings of ₩26.0B against cash of ₩14.4B. The share price is ₩2,155, down 44.6% over one year, and the data includes no news headlines.

What stands out

• Trailing revenue is ₩94.9B, slightly below the 2025 full year of ₩99.0B, and trailing operating income is roughly break-even at about ₩15M.
• Trailing net loss is about ₩532M, after profit of ₩1.2B in 2025 and ₩1.8B in 2024.
• Liabilities are 131% of equity and free cash flow is negative at about -₩2.4B on a trailing basis.
• The price is near its 52-week low of ₩1,945 and well below the high of ₩4,030; the year-end P/B ratio fell from 1.9 in 2021 to 0.6 in 2025 and the current P/B is 0.4.
• Filings in 2026 include a half-year report, a share buyback decision and results, a short-term borrowing increase, and an extraordinary shareholders' meeting, with no news headlines in the data.

What to watch

• The next full-year and quarterly results, to see whether operating profit turns into sustained net profit and whether free cash flow improves.
• Outcome of the short-term borrowing increase and the debt load against cash, given borrowings of about ₩26.0B.
• The reported 18.6% dividend yield is high relative to recent profits; the data does not say whether the dividend is sustainable, and no forecasts or analyst views are included.